Low response rate to ATG-based immunosuppressive therapy in very severe aplastic anaemia A Swedish nationwide cohort studyShow others and affiliations
2018 (English)In: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol. 100, no 6, p. 613-620Article in journal (Refereed) Published
Abstract [en]
ObjectivesAntithymocyte globulin (ATG)-based immunosuppression remains a cornerstone in aplastic anaemia (AA) treatment. However, most ATG studies are not population-based and knowledge about real-world results concerning response and outcome could offer important information for treating physicians. MethodsWe have recently performed a nationwide retrospective cohort study on all AA patients diagnosed in Sweden in 2000-2011 and now present treatment and outcome data on patients receiving first-line ATG. In total, 158 patients showed a 47.0% response rate which was similar in all age groups (range 41.5%-51.7%) with no difference regarding ATG formulation. The response was significantly associated with severity gradeespecially at time of treatment initiation: very severe (VSAA) 22.7%; severe (SAA) 54.5% (P<.001); and non-severe 88.5% (P<.001). A logistic regression-based predictive model indicated that VSAA patients with an absolute reticulocyte count <25x10(9)/L had only a 19% probability of response. In a multivariable analysis, age and VSAA at the time of treatment were the independent factors for inferior survival. ConclusionsReal-world VSAA patients respond poorly to ATG which indicates the need for a different treatment approach. Our findings suggest that age alone should not be a discriminating factor for administering ATG treatment.
Place, publisher, year, edition, pages
John Wiley & Sons, 2018. Vol. 100, no 6, p. 613-620
Keywords [en]
age, antithymocyte globulin, aplastic anaemia, real-world data, response rate
National Category
Hematology
Identifiers
URN: urn:nbn:se:uu:diva-357720DOI: 10.1111/ejh.13057ISI: 000434100400011PubMedID: 29532518OAI: oai:DiVA.org:uu-357720DiVA, id: diva2:1244334
2018-08-312018-08-312018-08-31Bibliographically approved